Education
About Us
Working with TipRanks
Follow Us
Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
PIQ Stock Chart & Stats
AU$0.67
AU$0.03(4.23%)
At close: 4:00 PM EST
AU$0.67
AU$0.03(4.23%)
Day’s Range― - ―
52-Week RangeAU$0.29 - AU$0.86
Previous CloseN/A
Volume90.30K
Average Volume (3M)426.90K
Market Cap
AU$62.77M
Enterprise ValueAU$51.18M
Total Cash (Recent Filing)AU$11.04M
Total Debt (Recent Filing)AU$277.74K
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding165,184,000
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.43Price Target Upside-35.82% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Streams (diagnostics + Lab Services)A two-channel business model—commercial diagnostics plus fee-for-service proteomics—provides structural revenue optionality. Contract lab work can generate repeatable, shorter-cycle cash flows to partially offset the longer commercialization timeline for diagnostics, reducing single-product dependence and smoothing revenue volatility over 2–6 months.
Proprietary Proteomics Diagnostics CapabilityOwning proteomics-based biomarker tests and related technical capabilities creates a durable competitive edge: proprietary assays enable differentiation, potential licensing, and long product lifecycles in diagnostics. This IP and specialist service capability support recurring testing revenue and barrier creation versus generic lab competitors.
Very Low Financial LeverageMinimal debt provides balance-sheet flexibility during a loss-making period, lowering default and covenant risk. Low leverage preserves capacity to fund R&D, commercialisation or strategic partnerships without immediate refinancing pressure, improving the company's ability to execute multi-month product adoption plans.
Bears Say
Steep Recent Revenue DeclineA ~72% drop in revenue is a structurally important signal: it erodes scale economics, reduces bargaining power with partners, and makes fixed-cost absorption harder. Sustained revenue contraction over multiple quarters undermines the firm's ability to invest in commercialization and threatens the viability of long-term diagnostics rollouts.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow implies ongoing cash burn that will pressure liquidity within months. Without material cash generation or external funding, negative OCF constrains R&D, marketing, and service capacity, and increases the likelihood of dilutive capital raises or scaled-back commercial plans.
Ongoing Unprofitable Operations And Negative ROEConsistent operating losses and negative ROE reduce internal funding for growth and weaken stakeholder confidence. Loss-making operations make it harder to attract partners or long-term customers, and signal that current business mix and cost structure are not yet delivering sustainable margin economics over the medium term.
Proteomics International Laboratories Ltd. News
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.28 and its highest was AU$0.86 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Proteomics International Laboratories Ltd.’s market cap is AU$62.77M.
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 11 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Aug 26, 2025. The company reported -AU$0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.026.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 165,184,000 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Proteomics International Laboratories Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
AU$0.43 (-35.82% Downside)
AU$0.43 (-35.82% Downside)
Blogger Sentiment
Bullish
AU:PIQ Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.16%
12-Months-Change
Fundamentals
Return on Equity
-71.87%
Trailing 12-Months
Asset Growth
35.92%
Trailing 12-Months
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.
PIQ Stock 12 Month Forecast
Average Price Target
AU$0.43
▼(-35.82% Downside)
Technical Analysis
Prescient Therapeutics Limited
―
Pharmaust Limited
―
Chimeric Therapeutics Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---